Kevin J Martin Selected Research

etelcalcetide hydrochloride

1/2022	Activation of the Calcium Receptor by Calcimimetic Agents Is Preserved Despite Modest Attenuating Effects of Hyperphosphatemia.
10/2020	One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidism.
10/2017	Effect of Etelcalcetide vs Placebo on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: Two Randomized Clinical Trials.
10/2017	Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial.
5/2015	A randomized, double-blind, phase 2 study evaluating the safety and efficacy of AMG 416 for the treatment of secondary hyperparathyroidism in hemodialysis patients.
2/2014	Velcalcetide (AMG 416), a novel peptide agonist of the calcium-sensing receptor, reduces serum parathyroid hormone and FGF23 levels in healthy male subjects.
1/2014	AMG 416 (velcalcetide) is a novel peptide for the treatment of secondary hyperparathyroidism in a single-dose study in hemodialysis patients.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kevin J Martin Research Topics

Disease

20	Secondary Hyperparathyroidism 01/2022 - 04/2002
19	Chronic Renal Insufficiency 08/2021 - 01/2004
8	Chronic Kidney Disease-Mineral and Bone Disorder (Renal Rickets) 08/2021 - 04/2002
8	Kidney Diseases (Kidney Disease) 01/2016 - 09/2004
6	Hyperparathyroidism 01/2016 - 09/2004
4	Hyperphosphatemia 01/2022 - 04/2004
4	Vascular Calcification 08/2021 - 02/2011
4	Vitamin D Deficiency 02/2011 - 09/2004
3	Bone Diseases (Bone Disease) 08/2021 - 03/2007
3	Renal Insufficiency (Renal Failure) 10/2019 - 04/2002
3	Pathologic Constriction (Stenosis) 05/2009 - 11/2004
2	Hypocalcemia 08/2021 - 10/2019
2	Nausea 10/2017 - 02/2014
2	Vomiting 10/2017 - 02/2014
2	Uremia 01/2016 - 03/2004
2	Inflammation (Inflammations) 03/2012 - 08/2011
2	Disease Progression 03/2012 - 08/2011
2	Hypertension (High Blood Pressure) 03/2012 - 08/2011
2	Cardiovascular Diseases (Cardiovascular Disease) 02/2011 - 04/2004
2	Fibrosis (Cirrhosis) 01/2004 - 04/2002
2	Bone Resorption 10/2002 - 04/2002
1	Primary Hyperparathyroidism 01/2018
1	Spasm (Spasms) 10/2017
1	Dehydration (Water Stress) 04/2016
1	Diarrhea 02/2014
1	Chronic Kidney Failure (Chronic Renal Failure) 09/2013
1	Osteoporosis 08/2012
1	Heart Diseases (Heart Disease) 08/2012
1	Obesity 05/2011
1	Liver Diseases (Liver Disease) 05/2011
1	Hemorrhage 05/2011
1	Disease Susceptibility (Diathesis) 05/2011
1	Magnesium Deficiency (Deficiency, Magnesium) 11/2009
1	Thrombosis (Thrombus) 05/2009
1	Varicose Veins (Varicose Vein) 10/2008
1	Esophageal and Gastric Varices (Esophageal Varices) 10/2008
1	Gastrointestinal Hemorrhage (Hematochezia) 10/2008
1	Metabolic Bone Diseases (Osteopenia) 03/2007
1	Wound Infection (Wound Infections) 09/2004
1	Hypercalcemia (Milk Alkali Syndrome) 04/2004
1	Proteinuria 01/2004
1	Acidosis 10/2002
1	Primary Myelofibrosis (Myelosclerosis) 04/2002

Drug/Important Bio-Agent (IBA)

18	Parathyroid Hormone (Parathormone)IBA 08/2021 - 10/2002
15	Vitamin D FDA LinkGeneric 08/2021 - 04/2004
15	MineralsIBA 08/2021 - 01/2004
10	Phosphorus (Red Phosphorus)IBA 01/2022 - 01/2003
9	CalciumIBA 01/2022 - 01/2003
8	Cinacalcet (Sensipar)FDA Link 01/2022 - 01/2003
7	etelcalcetide hydrochlorideIBA 01/2022 - 01/2014
6	Phosphates (Orthophosphate)IBA 08/2021 - 02/2005
6	SterolsIBA 10/2019 - 09/2004
3	paricalcitol (Zemplar)FDA Link 04/2014 - 05/2012
3	25-hydroxyvitamin DIBA 03/2012 - 09/2004
2	Hormones (Hormone)IBA 08/2021 - 03/2012
2	Peptides (Polypeptides)IBA 01/2015 - 01/2014
2	1,25-dihydroxyvitamin DIBA 03/2012 - 09/2008
2	Calcitriol (Calcijex)FDA LinkGeneric 08/2011 - 09/2004
2	Type 1 Parathyroid Hormone Receptor (Parathyroid Hormone Receptor)IBA 03/2004 - 10/2002
2	Messenger RNA (mRNA)IBA 01/2004 - 10/2002
2	Bone Morphogenetic Protein 7IBA 01/2004 - 04/2002
1	IonsIBA 01/2022
1	Calcimimetic AgentsIBA 01/2022
1	Fibroblast Growth Factor-23IBA 08/2021
1	Edetic Acid (EDTA)FDA Link 01/2018
1	KetonesIBA 04/2016
1	Alkenes (Olefins)IBA 04/2016
1	HydrogenIBA 04/2016
1	Dietary PhosphorusIBA 01/2016
1	Calcium-Sensing ReceptorsIBA 01/2015
1	Adrenal Cortex Hormones (Corticosteroids)IBA 08/2012
1	hydroxide ionIBA 08/2011
1	MagnesiumIBA 11/2009
1	Dipyridamole (Persantine)FDA LinkGeneric 05/2009
1	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 05/2009
1	Polytetrafluoroethylene (Teflon)FDA Link 02/2005
1	Adenylyl Cyclases (Adenylyl Cyclase)IBA 03/2004
1	CollagenIBA 01/2004
1	ProcollagenIBA 01/2004
1	Fibronectins (Fibronectin)IBA 01/2004
1	Proteins (Proteins, Gene)FDA Link 01/2004
1	Parathyroid Hormone-Related ProteinIBA 10/2002

Therapy/Procedure

13	Renal Dialysis (Hemodialysis) 01/2022 - 01/2003
11	Therapeutics 04/2014 - 01/2003
2	Catheters 10/2008 - 09/2004
1	Intravenous Administration 02/2014
1	Contraindications 05/2011
1	Central Venous Catheters 10/2008
1	Ligation 10/2008
1	Stents 02/2005
1	Thrombectomy 11/2004
1	Peritoneal Dialysis 09/2004
1	Parathyroidectomy 03/2004
1	Nephrectomy 04/2002
1	Electrocoagulation (Electrocautery) 04/2002